INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(54) Title: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS

(57) Abstract

Novel peptides capable of interacting with a hydrophobic structural determinant on a protein or peptide for amyloid or amyloid-like deposit formation inhibit and structurally block the abnormal folding of proteins and peptides into amyloid or amyloid-like deposits. Methods for preventing, treating or detecting disorders or diseases associated with amyloid-like fibril deposits, such as Alzheimer's disease and prion-related encephalopathies, are also provided.

PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS

5

CROSS-REFERENCE TO RELATED APPLICATION

The present application is a continuation-in-part of
10   U.S. Application No. 08/478,326, filed June 6, 1995, the
entire contents of which are hereby incorporated by reference.

GOVERNMENT LICENSE RIGHTS

15   The U.S. Government has a paid-up license in this
invention and the right in limited circumstances to require
the patent owner to license others on reasonable terms as
provided for by the terms of Grant No. 10953 awarded by
National Institutes of Health.

20

BACKGROUND OF THE INVENTION

Field of the Invention
25
This invention relates to the field of therapeutic
peptides for the prevention and treatment of disorders or
diseases resulting from abnormal formation of amyloid or
amyloid-like deposits, such as, but not limited to, prion-
30   related encephalophathies, Alzheimer's dementia or disease
(AD), and other amyloidosis disorders. This invention also
relates to the use of the peptides in preventing the formation
of or in promoting the redissolution of these insoluble
amyloid or amyloid-like deposits.

35

Description of the Background Art

Alzheimer's disease (AD) is the most common form of
dementia in adults (C. Soto et al. *J. Neurochem.* 63
40   :1191-1198, 1994), constituting the fourth leading cause of
death in the United States. Approximately 10% of the
population over 65 years old is affected by this progressive
degenerative disorder that is characterized by memory loss,
confusion and a variety of cognitive disabilities. One of the
45   key events in AD is the deposition of amyloid as insoluble
fibrous masses (amyloidogenesis) resulting in extracellular

neuritic plaques and deposits around the walls of cerebral
blood vessels. The main component of amyloid is a 4.1-4.3kDa
hydrophobic peptide, named amyloid β-peptide (Aβ), that is
codified in chromosome 21 as part of a much longer amyloid
5   precursor protein APP (Muller-Hill and Beyreuther, *Ann. Rev.
Biochem. 38:287-307, 1989). The APP starts with a leader
sequence (signal peptide), followed by a cysteine-rich region,
an acidic-rich domain, a protease inhibitor motif, a putative
N-glycosylated region, a transmembrane domain, and finally a
10 small cytoplasmic region. The Aβ sequence begins close to the
membrane on the extracellular side and ends within the
membrane. Two-thirds of Aβ faces the extracellular space, and
the other third is embedded in the membrane (Kang *et al.*
Nature 325:503-507, 1987; Dyrks *et al. EMBO J.* 7:949-957,
15 1988). Several lines of evidence suggest that amyloid may
play a central role in the early pathogenesis of AD.

        Evidence that amyloid may play an important role in
the early pathogenesis of AD comes primarily from studies of
individuals affected by the familial form of AD (FAD) or by
20 Down's syndrome. Down's syndrome patients have three copies
of APP gene and develop AD neuropathology at an early age
(Wisniewski *et al., Ann. Neurol.* 17:278-282, 1985). Genetic
analysis of families with hereditary AD revealed mutations in
chromosome 21, near or within the Aβ sequence (Forsell *et al.,*
25 *Neurosci. Lett.* 184:90-93, 1995). Moreover, recently it was
reported that transgenic mice expressing high levels of human
mutant APP progressively develop amyloidosis in brain (Games
et al., Nature 373:523-527, 1995). These findings appear to
implicate amyloidogenesis in the pathophysiology of AD.
30   Recently, the same peptide that forms amyloid
deposits in AD brain was also found in a soluble form (sAβ)
normally circulating in the human body fluids (Seubert *et
al., Nature* 359:355-327, 1992; Shoji *et al., Science*
258:126-129, 1992). It is believed that the conversion of sAβ
35 to insoluble fibrils is initiated by a conformational or
proteolytic modification of the 2-3 amino acid longer soluble
form. It has been suggested that the amyloid formation is a
nucleation-dependent phenomena in which the initial insoluble

- 3 -

"seed" allows the selective deposition of amyloid (Jarrett *et al.*, *Biochem.* 32 :4693-4697, 1993).

Peptides containing the sequence 1-40 or 1-42 of Aβ and shorter derivatives can form amyloid-like fibrils in the

5   absence of other protein (Pike *et al.*, *J. Neurosci.* 13:1676-1687, 1993), suggesting that the potential to form amyloid resides mainly in the structure of Aβ. The relation between the primary structure of Aβ and its ability to form amyloid-like fibrils was analyzed by altering the sequence of the

10 peptide. Substitution of hydrophilic residues for hydrophobic ones in the internal Aβ hydrophobic regions (amino acids 17-21) impaired fibril formation (Lorenzo *et al.*, *Proc. Natl. Acad. Sci. USA* 91:12243-12247, 1994), suggesting that Aβ assembly is partially driven by hydrophobic interactions.

15 Indeed, larger Aβ peptides (Aβ1-42/43) comprising two or three additional hydrophobic C-terminal residues are more amyloidogenic (Soto *et al.*, *J. Neurochem.* 63:1191-1198, 1994). Secondly, the conformation adopted by Aβ peptides is crucial in amyloid formation. Aβ incubated at different pH,

20 concentrations and solvents has mainly an α-helical (random coil) or a β-sheet secondary structure (Hilbich *et al.*, *J. Mol. Biol.* 228:460-473, 1992; Jarrett *et al.*, *Biochem* 32:4693-4697, 1993; Barrow *et al.*, *J. Mol. Biol.* 225:1075-1093, 1992). The Aβ peptide with α-helical or random coil structure

25 aggregates slowly; Aβ with β-sheet conformation aggregates rapidly (Burdick *et al.*, *J. Biol. Chem.* 267:546-554, 1992; Zagorski *et al.*, *Biochem.* 31:5621-5631, 1992; Soto *et al.*, *J. Biol. Chem.* 270:3063-3067, 1995). The importance of hydrophobicity and β-sheet secondary structure on amyloid

30 formation also is suggested by comparison of the sequence of other amyloidogenic proteins.

Analysis of Aβ aggregation by turbidity measurements indicates that the length of the C-terminal domain of Aβ influences the rate of Aβ assembly by accelerating nucleus

35 formation (Soto et al., *1994, supra*; Soto *et al*, *Neurosci. Lett.* 186:115-118, 1995). Thus, the C-terminal domain of Aβ may regulate fibrillogenesis. However, *in vitro* modulators of Aβ amyloid formation such as metal cations (Zn, Al) (Soto *et*

al., *Biochem. J.* 314:701-707, 1996; Jarrett *et al.*, *Cell* 73:1055-1058, 1993), heparan sulphate proteoglycans (Bush *et al.*, *Science* 265:1464-1467, 1994) and apoliprotein E (Exley *et al.*, *FEBS Lett.* 324:293-295, 1993) interact with the 12-28 region of Aβ. Moreover, mutations in the βPP gene within the N-terminal Aβ domain yield analogs more fibrillogenic (Soto *et al.*, 1995, *supra*; Buee *et al.*, *Brain Res.* 627:199-204, 1993; Strittmatter *et al.*, *Proc. Natl. Acad. Science. (USA)* 90:1977-1981, 1993; Wisniewski et al., Biochem. Biophys. Res. Commun. 179:1247-1254, 1991). Finally, while the C-terminal domain of Aβ invariably adopts a β-strand structure in aqueous solutions, environmental parameters determine the existence of alternative conformation in the Aβ N-terminal domain (Hilbich et al., 1992, *supra*; Burdick et al., 1992, *supra*). Therefore, the N-terminus may be a potential target site for inhibition of the initial random coil to β-sheet conformational change.

The emerging picture from studies with synthetic peptides is that Aβ amyloid formation is dependent on hydrophobic interactions of Aβ peptides adopting an antiparallel β-sheet conformation and that both the N- and C-terminal domains are important for amyloid formation. The basic unit of fibril formation appears to be the conformer adopting an antiparallel β-sheet composed of strands involving the regions 10-24 and 29-40/42 of the peptide (Pike et al., 1993, *supra*; Clements *et al.*, *Neurosci. Lett.* 161:17-20, 1993). Amyloid formation proceeds by intermolecular interactions between the β-strands of several monomers to form an oligomeric β-sheet structure precursor of the fibrillar β-cross conformation. Wood et al., 1995, *supra*, reported the inserting of aggregation-blocking prolines into proteins and peptides to prevent aggregation without affecting the structure or function of the native protein. In this manner, the authors suggest that novel proteins can be designed to avoid the problem of aggregation as a barrier to their production.

To date there is no cure or treatment for AD and even the unequivocal diagnosis of AD can only be made after postmortem examination of brain tissues for the hallmark

- 5 -

neurofibrillary tangles (NFT) and neuritic plaques. However, there are several recent publications outlining strategies for the treatment of Alzheimer's disease.

5   Heparin sulfate (glycosoaminoglycan) or the heparin sulfate proteoglycan, perlecan, has been identified as a component of all amyloids and has also been implicated in the earliest stages of inflammation-associated amyloid induction. Kisilevsky et al., *Nature Medicine* $\underline{1}$(2):143-148, (1995) describes the use of low molecular weight (135 - 1,000 Da)

10   anionic sulfonate or sulfate compounds that interfere with the interaction of heparin sulfate with the inflammation-associated amyloid precursor and the β-peptide of AD. Heparin sulfate specifically influences the soluble amyloid precursor (SAA2) to adopt an increased β-sheet structure characteristic

15   of the protein-folding pattern of amyloids. These anionic sulfonate or sulfate compounds were shown to inhibit heparin-accelerated Alzheimer's Aβ fibril formation and were able to disassemble preformed fibrils *in vitro* as monitored by electron micrography. Moreover, when administered orally at

20   relatively high concentrations (20 or 50 mM), these compounds substantially arrested murine splenic inflammation-associated amyloid progression *in vivo* in acute and chronic models. However, the most potent compound, poly-(vinylsulfonate), was acutely toxic.

25   Anthracycline 4'-iodo-4'-deoxy-doxorubicin (IDOX) has been observed clinically to induce amyloid resorption in patients with immunoglobin light chain amyloidosis (AL). Merlini et al., *Proc. Natl. Acad. Sci. USA* 92:2959-2963 (1995), elucidated its mechanism of action. IDOX was found to

30   bind strongly via hydrophobic interactions to two distinct binding sites (Scatchard analysis) in five different tested amyloid fibrils, inhibiting fibrillogenesis and the subsequent formation of amyloid deposits *in vitro*. Preincubation of IDOX with amyloid enhancing factor (AEF) also reduced the formation

35   of amyloid deposits. Specific targeting of IDOX to amyloid deposits *in vivo* was confirmed in an acute murine model. This binding is distinct from heparin sulfate binding as removal of the glycosaminoglycans from extracted amyloid fibrils with

- 6 -

heparinases did not modify IDOX binding. The common
structural feature of all amyloids is a β-pleated sheet
conformation. However, IDOX does not bind native amyloid
precursor light chains which suggests that the β-pleated sheet
5   backbone alone is not sufficient to form the optimal structure
for IDOX binding, and that it is the fibril cross-β-sheet
quaternary structure that is required for maximal IDOX
binding. It has been found that the amount of IDOX extracted
from spleens is correlated with amyloid load and not
10   circulating serum precursor amyloid levels. IDOX, however, is
also extremely toxic.

        The regulation and processing of amyloid precursor
protein (APP) via inhibition or modulation of phosphorylation
of APP control proteins has also been investigated in U.S.
15   Patent 5,385,915 and WO 9427603. Modulating proteolytic
processing of APP to nucleating forms of AD has also been
examined in AU 9338358 and EP569777. WO 95046477 discloses
synthetic peptides of composition X-X-N-X coupled to a
carrier, where X is a cationic amino acid and N is a neutral
20   amino acid, which inhibit Aβ binding to glycosoaminoglycan.
Peptides containing Alzheimer's Aβ sequences that inhibit the
coupling of α-1-antichymotrypsin and Aβ are disclosed in WO
9203474.

        Abnormal protein folding is also widely believed to
25   be the cause of prion-related encephalophathies, such as
Creutzfeldt-Jakob disease (CJD) and Gerstmann-Straussler-
Scheinker disease (GSS) in humans, scrapie in sheep and goats,
and spongiform encephalopathy in cattle.

        The cellular prion protein (PrP^c) is a
30   sialoglycoprotein encoded by a gene that in humans is located
on chromosome 20 (Oesch, B. et al., Cell 40:735-746, (1985);
Basler, K. et al., 46:417-428 (1986); Liao, Y.J. et al.,
Science 233:364-367 (1986); Meyer, R.K. et al., Proc. Natl.
Acad. Sci. USA 83:2310-2314 (1986); Sparkes, R.S. et al.,
35   Proc. Natl. Acad. Sci. USA 83:7358-7362 (1986); Bendheim, P.E.
et al. J. Infect. Dis. 158:1198-1208 (1988); Turk, E. et al.
Eur. J. Biochem. 176:21-30 (1988)). The PrP gene is expressed
in neural and non-neural tissues, the highest concentration of

mRNA being in neurons (Chesebro, B. et al., Nature 315:331-333
(1985); Kretzschmar, H.A. et al., Am. J. Pathol. 122:1-5
(1986); Brown, H.R. et al., Acta Neuropathol. 80:1-6 (1990);
Cashman, N.R. et al., Cell 61:185-192 (1990); Bendheim, P.E.,
5 Neurology 42:149-156 (1992)).

        The translation product of PrP gene consists of 253
amino acids in humans (Kretzschmar, H.A. et al., DNA 5:315-324
(1986); Pucket, C. et al., Am. J. Hum. 49:320-329 (1991)), 254
in hamster and mice or 256 amino acids in sheep and undergoes
10 several post-translational modifications. In hamsters, a
signal peptide of 22 amino acids is cleaved at the N-terminus,
23 amino acids are removed from the C-terminus on addition of
a glycosyl phosphatidylinositol (GPI) anchor, and asparagine-
linked oligosaccharides are attached to residues 181 and 197
15 in a loop formed by a disulfide bond (Turk, E. et al., Eur. J.
Biochem. 176:21-30 (1988); Hope, J. et al., EMBO J. 5:2591-
2597 (1986); Stahl, N. et al., Cell 51:229-240 (1987); Stahl,
N. et al., Biochemistry 29:5405-5412 (1990); Safar, J. et al.,
Proc. Natl. Acad. Sci. USA 87:6377 (1990)).

20   In prion-related encephalopathies, PrP^c is converted
into an altered form designated PrP^{Sc}, that is distinguishable
from PrP^c in that PrP^{Sc} (1) aggregates; (2) is proteinase K
resistant in that only the N-terminal 67 amino acids are
removed by proteinase K digestion under conditions in which
25 PrP^c is completely degraded; and (3) has an alteration in
protein conforamtion from α-helical for PrP^{Sc} to an altered
form (Oesch B. et al., Cell 40:735-746 (1985); Bolton, D.C. et
al., Science 218:1309-1311 (1982); McKinley, M.P. et al.,
Cells 35:57-62 (1982); Bolton, D.C. et al., Biochemistry
30 23:5898-5905 (1984); Prusiner, S.B. et al., Cell 38:127-134
(1984); Bolton, D.C. et al., Arch. Biochem. Biophys. 258:1515-
22 (1987)).

        Several lines of evidence suggest that PrP^{Sc} may be a
key component of the transmissible agent responsible for
35 prion-related encephalopathies (Prusiner, S.B. Science
252:1515-22 (1991)) and it has been established that its
protease-resistant core is the major structural protein of
amyloid fibrils that accumulate intracerebrally in some of

these conditions (Brendheim, P.E. et al., Nature 310:418-421
(1984); DeArmond, S.J. et al., Cell 41:221-235 (1985);
Kitamoto, T. et al., Ann. Neurol. 20:204-208 (1986); Robert,
G.W. et al., N. Engl. Med. 315:1231-1233 (1986); Ghetti, B. et
5 al., Neurology 39:1453-1461 (1989); Tagliavini, F. et al.,
EMBO J. 10:513-519 (1991); Kitamoto, T. et al., Neurology
41:306-310 (1991)).

Citation of any document herein is not intended as
an admission that such document is pertinent prior art, or
10 considered material to the patentability of any claim of the
present application. Any statement as to content or a date of
any document is based on the information available to
applicant at the time of filing and does not constitute an
admission as to the correctness of such a statement.
15

SUMMARY OF THE INVENTION

The present invention relates to peptides capable of
20 interacting or binding to a structural determinant on a
protein or peptide for amyloid or amyloid-like deposit
formation so as to inhibit or structurally block the abnormal
folding of the protein or peptide into an amyloid or amyloid-
like deposit, such as is observed in Alzheimer's disease,
25 amyloidosis disorders, prion-related encephalophathies, etc.
The peptide includes a hydrophobic cluster of at least three
hydrophobic amino acid residues, similar to those of the
protein or peptide with which they interact, where one of the
hydrophobic residues is preferably a proline residue. The
30 peptide according to the present invention may also include
charged amino acids at one or both ends of the peptide.

One object of the present invention is to overcome
the deficiencies of the prior art, including reducing the
toxicity and side effects in comparison to compounds and
35 therapeutic methods available in the prior art.

Another object of the present invention is to
provide a peptide having a hydrophobic cluster of amino acids
which blocks β-sheet formation between structural determinants

on proteins or peptides that leads to the aggregation of
abnormally folded proteins or peptides as amyloid or amyloid-
like deposits.

    A further object of the present invention is to
5 provide pharmaceutical compositions and methods for the
prevention or therapeutic treatment of disorders or diseases
associated with abnormal protein folding into amyloid or
amyloid-like deposits.

    Still another object of the present invention is to
10 provide a method for detecting disorders or diseases
associated with amyloid or amyloid-like fibril deposits.

BRIEF DESCRIPTION OF THE DRAWINGS

    Figures 1A-B provide a consensus sequence for
15 amyloidogenesis in terms of hydrophobicity and secondary
structure properties. Figure 1A is the primary structure of
the amyloidogenic sequence of peptides involved in the
formation of several amyloid deposits. The sequences
correspond to: amyloid β-peptide (SEQ ID NO: 1) found in
20 Alzheimer's disease, its Dutch variant and Downs Syndrome;
amyloid A (SEQ ID NO: 2) found in secondary amyloidosis and
familial Mediterranean fever; gelsolin amyloid (SEQ ID NO: 3)
related to familial amyloidosis of Finnish type; amyloid L
(SEQ ID NO: 4) found in immunoglobulin-related primary
25 amyloidosis; β2-microglobulin amyloid (SEQ ID NO: 5) found in
patients with chronic hemodialysis-related amyloidosis; and
apolipoprotein A1 amyloid (SEQ ID NO: 6) related to familial
amyloidotic polyneuropathy. Amino acids written in bold
correspond to hydrophobic residues and those underlined
30 represent positions with mutation related to the hereditary
form of the disease. Figure 1B provides the β-sheet
prediction for the 15 amino acid fragments containing the
sequences shown in Figure 1A. The solid bar represents
regions with a high probability of adopting a β-sheet
35 structure.

    Figures 2A-B provide the amino acid sequence for
several anti-amyloid peptides. Figure 2A shows the amino acid
sequences four anti-amyloid peptides labeled as anti-amyloid 1

- 10 -

(SEQ ID NO: 7), anti-amyloid 2 (SEQ ID NO: 8), anti-amyloid 3
(SEQ ID NO: 9) and anti-amyloid 4 (SEQ ID NO: 10). Hydro-
phobic amino acids are highlighted in bold. Figure 2B shows
the circular dichroism spectrum of the anti-amyloid peptide 1
5   (SEQ ID NO: 7) recorded as described in Example 1.

Figure 3 is a schematic representation of the β-
cross conformation for amyloid fibrils showing the crucial
importance of the interactions by hydrogen bonding between the
monomeric β-strand to form the intermolecular β-cross
10 structure.

Figures 4A-4B show the effect of anti-amyloid
peptide 1 having the sequence of SEQ ID NO: 7 on the amyloid
formation by Aβ in vitro. Amyloid formation was quantitated
by the fluorometric assay described in Example 1. Figure 4A
15 shows the dose-dependent inhibition of amyloidogenesis, using
anti-amyloid peptide 1 (shown as filled squares) and a 15
amino acid-non related peptide as a control (shown as unfilled
square). The incubation time was 24 hours at room temperature
and the Aβ concentration was 1 mg/ml in 0.1 M Tris, pH 7.4.
20 Figure 4B shows the effect of anti-amyloid peptide 1 (SEQ ID
NO: 7) on the amyloid formation after various incubation
times. The inhibitory effect of the peptide remained
unaltered over several days of incubation. Incubations
containing Aβ, alone, are depicted by unfilled squares;
25 incubations of Aβ, and a control peptide are depicted by
unfilled circles; and incubations of Aβ and anti-amyloid
peptide 1 are depicted by filled squares. The Aβ
concentration used was 1 mg/ml incubated in a molar ratio of
anti-amyloid peptide 1 or control peptide of 1:20. Neither
30 the anti-amyloid peptide 1 nor the control peptide gave
fluorescence values over the background level of 1-2
fluorescence units.

Figures 5A-C show electron micrographs of negative-
stained preparations of Aβ (Figure 5A), Aβ incubated with
35 anti-amyloid peptide 1 (Figure 5B) and anti-amyloid peptide 1
alone (Figure 5C). Aliquots of Aβ were incubated at 1 mg/ml
with or without the anti-amyloid peptide 1 in a molar ratio
1:50 (Aβ:anti-amyloid) for 6 days at room temperature.

- 11 -

Figures 6A-B show the effects of anti-amyloid
peptide 1 on the redissolution of preformed fibrils. Amyloid
fibrils were formed by incubating Aβ (1 mg/ml) for 3 days at
room temperature. Anti-amyloid peptide 1 was then added in a
5   molar ratio 1:50 (Aβ:anti-amyloid peptide 1). The incubation
was continued for 15 minutes, 6 hours or 24 hours and the
amyloid formation was quantitated by the fluorometric assay
(Figure 6A). Fluorescence values represent the amount of
amyloid formed. Figure 6B provides electron micrographs of the
10   nonincubated (left side picture) and incubated fibrils for 24
hours with anti-amyloid peptide 1 (right side picture).
Magnification is 50,000x.

Figures 7A-C show the physio-chemical
characterization of the amphoterin (HMG-1) derived amyloid
15   fragment, ATN$_p$. Figure 7A provides the amino acid sequence of
the fragment ATN$_p$ (SEQ ID NO: 11). Hydrophobic amino acid
residues are highlighted in bold. Figure 7B shows the
Chou-Fasman prediction for β-sheet structure of ATN$_p$. The
sequence with the highest β-sheet structure probability is
20   indicated with a bar. Figure 7C is an electron micrograph of
negative-stained preparations of ATN$_p$ with formed amyloid-like
fibrils.

Figure 8 is a bar graph showing the effect of
anti-amyloid peptide 1 on the amyloid formation by Aβ and of
25   peptides derived from the amyloidogenic sequence of gelsolin
amyloid and amyloid A. Either Aβ or the fifteen amino acid
peptides containing the amyloidogenic sequence of gelsolin
amyloid (SEQ ID NO: 12) and amyloid A (SEQ ID NO: 13) were
incubated in a concentration of 1 mg/ml for 24 hours without
30   and with anti-amyloid peptide 1 in a molar ratio of 1:5 or
1:20.

Figure 9 shows the structural characteristics of
iAβ. The amino acid sequence and β-sheet probability for iAβ
(SEQ ID No:8) and for the region of Aβ (SEQ ID No:14) used as
35   a template for iAβ is shown underneath the β-sheet probability
profile where the solid bar represents the region of Aβ having
a high probability of β-sheet structure.

Figure 10 shows the circular dichroism spectra of

- 12 -

iAβ at different peptide concentration.

Figure 11 shows the Aβ-iAβ interaction as quantitated by the quenching of the intrinsic fluorescence of Aβ (tyrosine 10) induced by the binding of iAβ. The inset
5 shows the fluorescence spectra of Aβ incubated alone or in the presence of 4 μM iAβ.

Figure 12 shows the dose-dependent inhibition of Aβ1-40 and Aβ1-42 fibrillogenesis by iAβ. Amyloid formation was quantitated by the fluorometric assay, as described in
10 Example 1. The Aβ concentration was 1 mg/ml in 0.1M Tris, pH 7.6 and an incubation time of 24h.

Figure 13 shows the effect of iAβ on amyloid formation by Aβ1-40, after different incubation periods. The molar ratio Aβ:iAβ (or control) was 1:20; Aβ concentration 1
15 mg/ml. Amyloid formation was quantitated as in Fig. 12. iAβ or the control peptide alone did not give fluorescence values above the background level.

Figures 14A and 14B shows the dissolution of preformed Aβ fibrils by iAβ in vitro. Amyloid fibrils were
20 first preformed by incubating Aβ1-40 or Aβ1-42 at a concentration of 1 mg/ml for 6 days at room temperature. Fluorometric quantitation of amyloid as described in Example 1. Fig. 14A shows the effect of different molar ratios of iAβ or control peptide on fibril disassembly after 24h of
25 incubation. Fig. 14B fibril dissolution induced by a 40-fold molar excess of iAβ or control peptide after different incubation periods at room temperature.

Figures 15a-f shows the electron microscopy analysis of the effect of iAβ on fibril formation and dissolution.
30 Aliquots of Aβ1-40 (2 mg/ml) were incubated at 37°C with or without iAβ or control peptide at a molar ratio 1:40 (Aβ:iAβ), centrifuged and the pellet loaded on electron microscopy grids, stained and visualized as described in the Materials and Methods. Fig. 15a shows Aβ incubated for 6 days; Fig. 15b
35 shows Aβ incubated with iAβ for 6 days; Fig. 15c shows Aβ incubated alone for 5 days and then for 1 day with iAβ; Fig. 15d shows iAβ incubated for 6 days at the same concentration as in Figs. 15b and c; Fig. 15e shows Aβ incubated with the

control peptide for 6 days; and Fig. 15f shows control peptide
incubated alone for 6 days at the same concentration used in
Fig. 15e.

Figure 16 shows the inhibition of amyloid formation
after long period of incubation (days) in the presence of low
concnetrations of iAβ. 30 μg of Aβ1-42 was incubated in 30μl
of 0.1M tris, pH 7.4 with a molar ratio 1:5 (Aβ:iAβ) of the
inhibitor for different times at room temperature. Amyloid
was quantitated by the thioflavine T fluorometric assay and
expressed as a percentage of the amount of amyloid incubated
for the same time in the absence of the inhitor.

Figure 17 shows the inhibition of Aβ fibrillogenesis
by iAβ containing all D-amino acids.

Figure 18 shows the effect of iAβ on the promotion
of Aβ fibrillogenesis induced by apolipoprotein E. 30 μg of
Aβ1-40 were incubated with or without 2.4μg of human plasma
apolipoprotein E (apoE). Samples of Aβ alone or Aβ/apoE were
incubated also with 1:10 (Aβ:iAβ) of the inhibitor. All the
incubators were performed for 24h at room temperature.
Amyloid formation was evaluated by the thioflavine T
fluorometric assay. The average of two different experiments
is shown.

Figure 19 shows Alzheimer's amyloid plaque
dissolution by iAβ.

Figure 20 shows the effect of iAβ on the Aβ-induced
cell toxicity.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Novel peptides specifically designed to interfere
with the β-sheet conformation of precursor proteins or
peptides involved in the formation of amyloid or amyloid-like
deposits were developed. The present invention is directed to
these novel peptides, pharmaceutical compositions containing
one or a mixture of such peptides of the invention, and
methods for preventing, treating, or detecting disorders or
diseases associated with abnormal protein folding into amyloid
or amyloid-like deposits.

It has now been found that while the amino acid
sequence of proteins from different amyloid or amyloid-like
deposits differ, all of these amyloidogenic proteins or
peptides contain a segment having the common characteristic of
5   a hydrophobic cluster of hydrophobic amino acids (mainly
phenylalanine, valine, alanine, leucine, isoleucine) being
present within a larger segment strongly predicted to have a
β-sheet conformation (Figs. 1A and 1B). The hydrophobic
cluster is believed to determine the binding of protein or
10 peptide monomers resulting in aggregation, whereas the longer
sequence, of which the hydrophobic cluster is a part, is
believed to control the ordering of the aggregates into a β-
cross conformation (β-cross quaternary fibril structure)
typical of amyloid fibril structure (Fig. 3). Even a non-
15 amyloid related peptide, which contains a potential
amyloidgenic sequence motif (Figs. 7A and 7B) such as obtained
by proteolysis of amphoterin, forms typical amyloid-like
fibrils *in vitro* (Fig. 7C).

        The novel peptides of the present invention contain
20 at least three hydrophobic amino acid residues forming a so-
called "hydrophobic cluster". In addition, these novel
peptides may contain more than three hydrophobic amino acid
residues within the hydrophobic cluster, and/or may contain
other amino acid residues outside of the hydrophobic cluster
25 that also act to lower the propensity of the peptide to adopt
a β-sheet conformation and/or increase the solubility of the
peptide in an aqueous physiological medium. Preferably, the
peptides of the present invention have a sequence of between
three and fifteen amino acid residues and contain a
30 hydrophobic core of three to eight hydrophobic amino acid
residues in the middle of the sequence in addition to a
charged amino acid residue, such as aspartic acid, glutamic
acid, arginine, or lysine, at one end of the peptide. Most
preferably, a charged hydrophilic amino acid residue is
35 present at both ends of the peptide.

        While prion protein PrP normally assumes an α-
helical conformation, it is believed that abnormal protein
folding alters the normal PrP conformation to an abnormal β-

- 15 -

sheet conformation. In any event, inhibitor peptides designed
to bind to PrP prevents abnormal protein folding into a
altered conformation resulting in amyloid or amyloid-like
deposits.

5   In this invention, the peptides capable of
interacting or binding with a structural determinant on a
protein or peptide involved in amyloid or amyloid-like deposit
formation, which inhibits the abnormal folding of the protein
or peptide, were designed with a knowledge of the structural
10   determinants for amyloid formation. Peptides having a
hydrophobic region which interacts with a structural
determinant of the protein or peptide, but with a very low
probability of adopting a β-sheet conformation, are designed
to bind to the structural determinant and function as an
15   inhibitor of amyloid fibril formation or as an agent that
dissolves preformed amyloid fibrils.

             The peptides of the invention also contain at least
one β-sheet blocking amino acid, such as Pro, Gly, Asn, or
His, within the hydrophobic cluster so as to prevent the
20   binding of protein or peptide monomers into aggregates and the
ordering of such aggregates into an altered conformation such
as the β-cross conformation typical of amyloid fibril
structure. While the peptides can be designed to be partially
homologous to the structural determinant they are to interact
25   with, amino acid homology is unnecessary as long as the
peptide have a hydrophobic core or cluster of sufficient
hydrophobicity so that it will interact strongly with the
structural determinant to structurally block abnormal protein
or peptide folding into fibril deposits.

30   It will be appreciated by those in the art that
besides the twenty common naturally occurring amino acids,
modified amino acids or naturally occurring but rare amino
acids can also be incorporated into the peptides of the
present invention. For instance, it was demonstrated that a
35   peptide with amino acid residues in the D-form inhibited
fibrillogenesis of Aβ just as well as the peptide with the
same sequence of amino acids in the L-form (see Example 1).

             Modifications to amino acids in the peptides of the

invention include, but are not limited to, an amide moiety or a pyroglutamyl residue. These modifications may contribute to decreasing the propensity to form β-sheet conformation or may contribute to peptide stability, solubility, or even

5 immunogenicity. A more stable, soluble and less immunogenic peptide is desirable. Many neuropeptides modified at the C-terminus with a $CONH_2$ (amide) group appear to be resistant to attack by carboxypeptidases and many neuropeptides having a pyroglutamyl residue at the N-terminus are more resistant to

10 attack by broad specificity aminopeptides. Also included as peptides of the present invention are cyclic peptides that are resistant to attack by both carboxypeptidases and aminopeptidases.

Non-limiting examples of peptides designed to

15 inhibit abnormal folding in the formation of amyloid and amyloid-like deposits are presented in Table 1. The anti-PrP peptides are designed to bind to the structural determinant of PrP corresponding to amino acid residues 114 to 125 of prion (presented as SEQ ID NO:23). While Pro is used as the β-sheet

20 blocking amino acid in the peptides presented in Table 1, it is expected that other β-sheet blockers, such as Gly, Asn and His, are suitable and would work equally well.

- 17 -

Table 1

Examples of Peptides Inhibiting Abnormal Protein Folding

1. Anti-amyloid peptides

          SEQ ID NO:7
          SEQ ID NO:8   (iAβ)
          SEQ ID NO:9
          SEQ ID NO:10

    a)   shorter derivatives of iAβ (SEQ ID NO:8)

          SEQ ID NO:15
          SEQ ID NO:16
          SEQ ID NO:17
          SEQ ID NO:18
          SEQ ID NO:19
          Pro-Phe-Phe

    b)   derivatives of iAβ with higher hydrophobicity

          SEQ ID NO:20
          SEQ ID NO:21
          SEQ ID NO:22

2. Anti-prion (PrP) peptides

          SEQ ID NO:24
          SEQ ID NO:25

        It is preferable that a structural determinant is
identified and a peptide is designed having a hydrophobic core
or cluster which can bind to the structural determinant and
structural block abnormal folding and prevent the formation of
fibril deposits. However, the prior identification of the
structural determinant may not always be necessay.

        Methods for predicting protein conformation to aid
in the design of peptide that have a hydrophobic cluster and a
low probability of abnormally folding into an altered
conformation such as a β-sheet are described in Chou and
Fasman *Ann. Rev. Biochem.* 47:251-276, 1978, Garnier *et al.*, *J.*

- 18 -

Mol. Biol. 120:97-120, 1978, and Minor *et al. Nature* 371:264-267., 1994.

As a method of preventing or treating a disorder or disease associated with amyloid or amyloid-like deposits, the

5   inhibitory peptide of the present invention is administered in an effective amount to a subject in need thereof, where the subject can be human or animal. Likewise, a method of detecting such disorders or diseases also includes administering a sufficient amount of the designed peptide to

10 visualize its binding to fibril deposits by well known imaging techniques.

As used herein, the term "prevention" of a condition, such as Alzheimer's disease or other amyloidosis disorders, in a subject involves administering a peptide

15 according to the present invention prior to the clinical onset of the disease. "Treatment" involves administration of the protective peptide after the clinical onset of the disease. For example, successful administration of the peptide of the present invention, after development of a disorder or disease

20 comprises "treatment" of the disease. The invention is useful in the treatment of humans as well as for veterinary uses in animals.

The peptides of the present invention may be administered by any means that achieves its intended purpose.

25 For example, administration may be by a number of different parenteral routes including, but not limited to, subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intracerebral, intranasal, oral, transdermal, or buccal routes. Parenteral administration can be bolus injection or

30 by gradual perfusion over time.

A typical regimen for preventing, suppressing, or treating a condition associated with amyloid or amyloid-like deposits, comprises either (1) administration of an effective amount in one or two doses of a high concentration of

35 inhibitory peptides in the range of 0.5 to 10 mg of peptide, more preferably 0.5 to 5 mg of peptide, or (2) administration of an effective amount of the peptide administered in multiple doses of lower concentrations of inhibitor peptides in the

range of 10-1000μg, more preferably 50-500μg over a period of
time up to and including several months to several years.

It is understood that the dosage administered will
be dependent upon the age, sex, health, and weight of the

5   recipient, kind of concurrent treatment, if any, frequency of
treatment, and the nature of the effect desired. The total
dose required for each treatment may be administered by
multiple doses or in a single dose. By "effective amount", it
is meant a concentration of inhibitor peptide(s) which is

10   capable of slowing down or inhibiting the formation of amyloid
or amyloid-like deposits, or of dissolving preformed fibril
deposits. Such concentrations can be routinely determined by
those of skill in the art. It will also be appreciated by
those of skill in the art that the dosage may be dependent on

15   the stability of the administered peptide. A less stable
peptide may require administration in multiple doses.

Preparations for parenteral administration include
sterile aqueous or non-aqueous solutions, suspensions, and
emulsions, which may contain auxiliary agents or excipients

20   which are known in the art. Pharmaceutical compositions such
as tablets and capsules can also be prepared according to
routine methods.

Pharmaceutical compositions comprising the peptides
of the invention include all compositions wherein the

25   peptide(s) are contained in an amount effective to achieve its
intended purpose. In addition, the pharmaceutical
compositions may contain suitable pharmaceutically acceptable
carriers comprising excipients and auxiliaries which
facilitate processing of the active compounds into

30   preparations which can be used pharmaceutically. Suitable
pharmaceutically acceptable vehicles are well known in the art
and are described for example in Gennaro, Alfonso, Ed.,
Remington's Pharmaceutical Sciences, 18th Edition 1990, Mack
Publishing Co., Easton, PA, a standard reference text in this

35   field. Pharmaceutically acceptable vehicles can be routinely
selected in accordance with the mode of administration and the
solubility and stability of the peptides. For example,
formulations for intravenous administration may include

sterile aqueous solutions which may also contain buffers,
diluents and other suitable additives.

Suitable formulations for parenteral administration
include aqueous solutions of the active compounds in water-
5   soluble form, for example, water-soluble salts. In addition,
suspension of the active compound as appropriate oily
injections suspensions may be administered. Suitable
lipophilic solvents or vehicles include fatty oils, for
example, sesame oil, or synthetic fatty acid ester,s for
10   example ethyl oleate or triglycerides. Aqueous injection
suspensions that may contain substances which increase the
viscosity of the suspension include, for example, sodium
carboxymethyl cellulose, sorbitol, and/or dextran.
Optionally, the suspension may also contain stabilizers.

15   Disorders or diseases associated with abnormal
protein folding into amyloid or amyloid-like deposits to be
treated or prevented by administering the pharmaceutical
composition of the invention includes, but is not limited to,
Alzheimer's disease, FAF, Down's syndrome, other amyloidosis
20   disorders, human prion diseases, such as Kuru, Creutzfeldt-
Jakob Disease (CJD), Gerstmann-Straussler-Scheinker Syndrome
(GSS), prion associated human neurodegenerative diseases as
well as animal prion diseases such as scrapie, spongiform
encephalopathy, transmissible mink encephalopathy and chronic
25   wasting disease of mule deer and elk.

Besides preventative and therapeutic treatments, the
peptides of the invention may also be administered to detect
and diagnose the presence or absence of amyloid or amyloid-
like deposits *in vivo*. A designed peptide capable of binding
30   to structural determinants in a corresponding amyloid or
amyloid-like deposit, labeled non-radioactively or with a
radioisotope, as is well-known in the art, can be administered
to a subject for diagnosing the onset or presence of a disease
or disorder associated with abnormal protein folding into
35   amyloid or amyloid-like fibril deposits. The binding of such
a labeled peptide after administration to amyloid or amyloid-
like deposits can be detected by *in vivo* imaging techniques
known in the art.

- 21 -

Having now generally described the invention, the
same will be more readily understood through reference to the
following example which is provided by way of illustration and
is not intended to be limiting of the present invention.

5

EXAMPLE 1

Amyloid deposition appears to be an important factor
10   in the development of neuritic plaque and neuronal disfunction
in AD. The results of the study presented below indicate that
a short peptide partially homologous to the central
hydrophobic region of $A\beta$ (residues 17-21), but containing
amino acids which block the adoption of a β-sheet structure
15   binds $A\beta$, inhibits amyloid formation *in vitro* and dissolves
preformed $A\beta$ fibrils. Furthermore, the inhibitor is able to
block the *in vivo* deposition of AA in the spleen of mice.
Since the inhibition of fibrillogenesis and the disassembly of
preformed fibrils occurs in the presence of a molar excess of
20   an 11 amino acid peptide, called inhibitor of $A\beta$
fibrillogenesis peptide (i$A\beta$) and also designated as anti-
amyloid peptide 2, the $A\beta$-$A\beta$ interaction probably has a
greater affinity that the $A\beta$-i$A\beta$ interaction. Although a
molar excess of i$A\beta$ is required to produce the inhibition of
25   amyloid formation the very low concentration of s$A\beta$ present in
human body fluids (1-10 nM) would necessitate only 40-400 nM
of i$A\beta$ for a 4-fold molar excess.

The results of the study support the concept that
the formation of a β-sheet secondary structure is important
30   for fibrillogenesis and we believe that i$A\beta$ inhibits amyloid
formation by binding to monomeric $A\beta$ peptides thereby blocking
the formation of the oligomeric β-sheet conformation precursor
of the fibrils. The dissolution of preformed fibrils induced
by i$A\beta$ may indicate that the monomeric peptide is in
35   equilibrium with the fibrils, as previously suggested (Levin,
M. *et al.*, *J. Clin. Invest.* 51:2773-2776, 1972; Kisilevsky, R.
et al., *Lab. Invest.* 48:53-59, 1983). The inhibitor may bind
to monomeric peptide, thus displacing the equilibrium, and

leading to fibril disaggregation.

MATERIAL AND METHODS

Peptide synthesis. Synthetic peptides containing the sequence 1-40, 1-42 of Aβ and the anti-amyloid peptides were synthesized by a solid phase technique on a p-methyl-benzhydrylamine resin using a Biosearch SAM 2 synthesizer. Peptides were subjected to purification by high performance liquid chromatography (HPLC) with the use of a reverse-phase support medium (Delta-Bondapak) on a 0.78 x 30 cm column with a 0-80% linear gradient of acetonitrile in 0.1% (v/v) trifluoroacetic acid. The peptide content of the eluate was monitored by measurement of its absorption at 220 nm. Peptide sequences were determined by automatic Edman degradation on a 477A protein sequencer and the PTH derivatives analyzed with an on-line 120 A PTH analyzer (Applied Biosystems, Foster City, CA). Purity of the peptides was evaluated by peptide sequencing and laser desorption mass spectrometry. Stock solutions of the peptides were prepared by dissolving them in 50% acetonitrile. The concentration was determined by amino acid composition analysis on a Waters Pico-Tag amino acid analyzer (Millipore Corp, Bedford, MA), after hydrolyzing the samples under reduced pressure in the presence of 6M HCl for 20 hours at 110°C. For experiments, peptide aliquots were lyophilized and resuspended in the buffer used in the assay.

Prediction of Secondary Structure. The α-helix, β-sheet and β-turn propensities for different sequences were calculated by the Chou and Fasman secondary structure prediction algorithm (Chou and Fasman, *Ann. Rev. Biochem.* **47**: 251-2760, 1978) using the program Protylze version 3.01 from Copyright.

Fluorimetric determination of amyloid formation. Aliquots of peptides were incubated for varying amounts of time at room temperature in 0.1M Tris-HCl, pH 7.4. To quantitate amyloid formation, a thioflavine T (ThT) fluorescence method was used. ThT binds specifically to

- 23 -

amyloid and this binding procedure produces a shift in its
emission spectrum and a fluorescent signal proportional to the
amount of amyloid formed (Naiki et al., Lab. Invest.
65:104-110, 1991). Thus, this method is very specific for the
5   semiquantitation of amyloid-like aggregates. After incubation
Aβ peptides were added to 50 mM glycine, pH 9.2, 2 μM ThT in a
final volume of 2 ml. Fluorescence was measured at an
excitation wavelength of 435 nm and an emission wavelength of
485 nm using a Hitachi F-2000 fluorescence spectrometer
10 (Hitachi Instruments Inc., San Jose, CA). A time scan of
fluorescence was performed and three values after the decay
reached the plateau (280, 290 and 300 seconds) were averaged
after subtracting the background fluorescence of 2 μM ThT.

15   **Electron microscopy.** For fibril formation, peptides
(1 mg/ml) were incubated in 0.1 M Tris-HCl, pH 7.4, for 6 days
at room temperature. Samples to be visualized were placed on
carbon formvar-coated 300-mesh nickel grids for 1 minute,
blotted and stained for 1 minute with 2% uranyl acetate under
20 a vapor of 2% glutaraldehyde and visualized on a Zeiss EM 10
electron microscope (Carl Zeiss, Inc., Thornwood, NY) at 80
kV.

           Circular dichroism studies. The secondary structure
25 of Aβ and inhibitor peptides was analyzed by circular
dichroism in aqueous solution. Spectra were recorded in a
Jasco spectropolarimeter Model J-720 (Jasco Inc., Easton, MD).
Aliquots of peptides at a concentration of 0.1-0.2 mg/ml in 20
mM Tris-HCl, pH 7.4, were first centrifuged to produce a clear
30 solution and the spectra were recorded at 1 nm intervals over
the wavelength range 190 to 260 nm in a 0.1 cm pathlength
cell. Results are expressed in terms of mean residue
ellipticity in units of deg $cm^2 dmol^{-1}$.

           Binding sites. The interaction between Aβ an iAβP
35 was studied by fluorescence spectroscopy at 25°C using a
Perkin Elmer model LS50B spectrofluorimeter. 45 μg of Aβ1-40
was dissolved in 300 μl of 5 mM Tris, pH 7.4 and immediately
the fluorescence spectra was recorded between 290nm an 400nm
at excitation 280nm, with slits set at 2.5nm bandwidth.

Different amounts of lyophilized iAβ were added to the Aβ solution and after 15 min of incubation the fluorescence spectra was recorded, iAβ at the same concentrations did not give any fluorescence signal above the background. The

5 binding of iAβ to Aβ was evaluated by the change in fluorescence intensity at 309nm between the spectra of Aβ alone and in the presence of different concentrations of the inhibitor. The binding data were analyzed with the aid of a curve fitting software (GraphPad Prism version 1.0).

10   **Fluorometric quantitation of fibrillogenesis.** The assay used was based on fluorescence emission by ThT, as described previously (Burdick et al., 1992, *supra*). Aliquots of Aβ at a concentration of 1mg/ml prepared in 0.1M Tris, pH 7.4 were incubated for different times in the absence or in

15 the presence of different concentrations of iAβ. In order to evaluate the inhibition of amyloid formation and dissolution of preformed fibrils, the inhibitor peptide was added at the beginning of the incubation or after 6 days of incubation of Aβ alone. At the end of the incubation period, 50 mM glycine,

20 pH 9.2, 2 μM thioflavine T was added in a final volume of 2 ml. Fluorescence was measured at excitation 435 nm and emission 485 nm in a Perkin Elmer, model LS50B fluorescence spectrometer.

        In vivo studies using the experimental murine model

25 **of amyloidosis.** Induction of experimental amyloidosis was done as previously described (LeVine et al., *Protein Sci.* 2:404-410, 1993; Snow et al., *J. Histochem. Cytochem.* 39:1321-1330, 1991). BALB/c mice were injected t.v. with 100μg of amyloid enhancing factor (AEF) alone or preincubated for 24h

30 with 5 mg of iAβ. AEF was prepared using the standard protocols (Merlini et al., *Proc. Natl. Acad. Sci. USA* 92:2959-2964, 1995). The AEF injection was followed by a single s.c. injection of 0.5ml of 2% silver nitrate. Animals were sacrificed 5 days after the injection and the amyloid

35 quantitated by immunohistochemistry and congo red staining. A standard set of amyloid containing tissue was generated (5%, 10%, 20%, 30%, 40%, 50%). These were reference points to determine the amount of amyloid in a given tissue. Standard

sections were examined under the microscope (Nikon, using
polarizing filters to generate birefringence for Congo red).
The images were digitized and transferred to a MacIntosh
computer for analysis. The digitized images were analyzed for

5   color (intensity and area) under low power (20X) using a
Kontron or Prism Image Analysis. Experimental spleen tissue
sections were fixed in 10% buffered formalin and embedded in
paraffin and stained with antibodies against SAA. The
experimental sections were analyzed and compared to the

10   standards for quantitation of the area spleen containing
amyloid. The experiments were performed using four animals
per condition.

RESULTS

15   **Design of inhibitor peptides.** Our laboratory
focused on the central hydrophobic region within the
N-terminal domain of Aβ, amino acids 17- 21 (corresponding to
amino acid residues 2-6 of SEQ ID NO:1), as a model for our
inhibitor peptide (Figs. 2A and 9). Proline residues were

20   introduced in the inhibitor peptide in order to block β-sheet
structure and charged residues were added at the ends of the
peptide to increase solubility. Proline was chosen to block
β-sheet structure since it rarely forms part of this
conformation (Chou et al., Ann. Rev. Biochem. 47:251-276,

25   1978) and does not occurs in the interior of antiparallel β-
sheets (Wouters et al., Protein Sci. 3:43S, 1994), due to the
extraordinary characteristics of this amino acid, namely: (a)
the nitrogen of the peptide bond is not available to the
β-sheet bonding network; (b) the torsion angles of the

30   peptidyl-propyl bond imposed by the proline ring are
incompatible with peptide bond geometries found in β-sheet
motifs; and (c) the proline ring can not fit sterically within
the β-sheet bonding network. Moreover, recent data showed
that the introduction of proline residues into short peptides

35   homologous to Aβ resulted in non-amyloidogenic analogues
((Wood et al., Biochem. 34:724-730, 1995).

        Based on these criteria, an 11 amino acid peptide,
called inhibitor of Aβ fibrillogenesis peptide (iAβ) was
designed, which has a low probability of adopting a β-sheet

conformation due to the presence of proline residues (Fig. 9). Other peptide inhibitors based on the above criteria are shown in Fig. 2A. The circular dichroism spectrum of iAβ in aqueous solution was typical of unordered structures (Fig. 10).

5   Samples of iAβ at different concentrations as well as samples incubated for several days have similar spectra (Fig. 10). Indeed, iAβ did not aggregate even at high concentrations (4 mg/ml) or after long periods of incubation (more than 30 days).

10   The interaction between Aβ and iAβ was studied by monitoring the quenching of Tyr^{10} fluorescence of Aβ (Fig. 11). Fluorescence spectroscopy was chosen to study the interaction of Aβ-iAβ because this technique has been used extensively for ligand-binding studies and does not require peptide labelling with reagents that may alter their properties. Aβ excited at

15 280nm showed a fluorescence spectrum with a maximum at 309nm (Fig. 11, inset), which is typical of tyrosine emission. The presence of iAβ induced a saturable quenching of the fluorescence, reaching a maximum of 12.6% of the total

20 fluorescence at approximately 4 μM of iAβ (Fig. 11). Non-linear regression analysis of the binding data to a rectangular hyperbola allowed calculation of a relative dissociation constant of 75.9 ± 6.5 nM.

          Inhibition of Aβ amyloid formation and dissolution

25 **of preformed fibrils** *in vitro.* The quantitative evaluation of the effect of iAβ on *in vitro* Aβ fibrillogenesis was based on a fluorometric assay that measures thioflavine T (ThT) fluorescence emission (Soto et al., 1995, *supra*). The binding of ThT to amyloid is specific and produces a shift in the

30 emission spectrum of ThT and a fluorescent enhancement proportional to the amount of amyloid (LeVine et al., 1993, *supra*). Figure 12 shows the influence of different concentrations of iAβ on fibrillogenesis of the two major variants of Aβ (Aβ1-40 and Aβ1-42). iAβ inhibited in a

35 dose-dependent manner *in vitro* amyloid formation by both Aβ variants. After 24h of incubation in the presence of a 5-fold or 20-fold molar excess of iAβ, Aβ1-40 formed only 33.9% and 13.7%, respectively, of the amyloid detectable in the absence

- 27 -

of inhibitor (Fig. 12). Although the inhibitor is less
efficient with Aβ1-42, a 5-, 20-, and 40-fold molar excess of
iAβ over Aβ1-42 resulted in a 28.7%, 72.3% and 80.6% of
inhibition, respectively (Fig. 12). Several non-related
5   peptides had no effect on fibrillogenesis or slightly
increased Aβ amyloid formation, probably by incorporation into
the fibrils. The 12 residue control peptide (SEQ ID NO:26),
did not alter amyloid formation by Aβ1-40 or Aβ1-42 (Figs. 12
and 13). iAβ inhibited Aβ amyloid formation even after
10 extensive incubation (Fig. 13) and appeared to be a more
efficient blocker of fibrillogenesis after several days of
incubation.

      The 15-amino acid peptide, designated anti-amyloid
peptide 1 (SEQ ID NO:7) was found to adopt a random coil
15 conformation (Fig. 2B) and was also found to be 90% inhibitory
to amyloid fibril formation at 50-fold molar excess over
soluble amyloid monomers (Figs. 4A, 4B, 5A and 5B).

      In order to evaluate the ability of iAβ to
disassemble preformed Aβ fibrils, Aβ1-40 or Aβ1-42 (1 mg/ml)
20 were preincubated for 5 days at 37°C before the addition of
inhibitor peptide. Fig. 14A shows the dissolution of Aβ1-40
or Aβ1-42 fibrils after 24h incubation with different iAβ
concentrations. The inhibitor efficiently affected
disaggregation of Aβ1-40 fibrils, achieving almost complete
25 dissolution when used in a 40-fold molar excess. Conversely,
only 51% of Aβ1-42 fibril reduction was obtained with the same
molar excess of iAβ (Fig. 14). The maximum level of fibril
dissolution was obtained after 2 days of incubation with iAβ
and remained unaltered thereafter (Fig. 14B).

30   The D-form of iAβ to inhibit Aβ fibrillogenesis was
compared to the L-form of iAβ and the results shown in Fig. 17
demonstrate that D-iAβ inhibits Aβ fibrillogenesis similarly
to L-iAβ. Aβ1-42 (1 mg/ml) was incubated for 24h in the
presence of different molar ratios of the L- and D-form of
35 iAβ. Amyloid was quantitated by the fluorometric assay based
on the thioflavine T fluorescence emission and expressed as a
percentage of the amyloid obtained in the Aβ sample non-
incubated with the inhibitor.

- 28 -

The inhibition of fibril formation and the dissolution of preformed fibrils by iAβ was also analyzed by negative-staining electron microscopy (Figs. 15a-f). Aβ1-40 (2 mg/ml) preincubated for 6 days at 37°C formed typical 8-10

5 nm unbranched fibrils (Castano et al., biochem. Biophys. Res. Commun. 141:782-789, 1986) (Fig. 15a). When Aβ was incubated from the start with a 40-fold excess of iAβ, only amorphous aggregates were obtained (Fig. 15b). The control peptide under the same conditions did not produce any effect on Aβ

10 fibrillogenesis (Fig. 15e). Fibrils preformed by incubation of Aβ1-40 for 6 days at 37°C were almost completely dissolved after 2 days of incubation with a 1:40 molar ratio of Aβ:iAβ (Fig. 15c). iAβ or the control peptide incubated under the same conditions used in the experiments shown in Figs. 15b and

15 15e, formed no amyloid-like material (Figs. 15d and 15f).

Dissolution of preformed fibrils also occurred with the 15 amino acid anti-amyloid peptide 1 (Figs. 6A and 6B). This anti-amyloid peptide also inhibits the fibril formation of other amyloidgenic peptides derived from various other

20 amyloid material, e.g., amyloid-A and the gelsolin related amyloid (Fig. 8).

Inhibition of *in vivo* fibrillogenesis using an animal model of amyloidosis related to amyloid-A. A well-characterized mouse model for systemic amyloid-A (AA)

25 deposition was used. This model has been used to test the role of amyloid-associated components such as proteoglycans and apolipoprotein E (Kindy et al., Lab. Invest. 73:469-476, 1995; Snow et al., 1991, *supra*) and to test inhibitors of amyloid deposition *in vivo* (Kisilevsky et al., Nature Med.

30 1:143-148, 1995; Merlini et al., 1995, *supra*). Secondary or reactive amyloidosis is an inflammation-associated disorder in which AA protein is deposited in several organs. The AA protein is a 76 residues N-terminal fragment derived from proteolysis of a precursor called serum amyloid A (SAA)

35 protein (Levin et al., 1972, *supra*).

Experimental amyloidosis in mice was induced by injection of amyloid enhancing factor (AEF) and silver nitrate. Under these conditions the animals developed amyloid deposits in the

- 29 -

spleen after 36-48 h of the injection (Kisilevsky et al.,
1983, *supra*). We examined the effect of iAβ on AA amyloid
formation after 5 days. When 5 mg of iAβ were injected
together with AEF, after 24h of preincubation, the area
5   occupied by amyloid in the spleen was decreased in
approximately 86.4% in comparison with the animals treated
without the inhibitor (Table 2).

Table 2: Effect of IAβ on *in vivo* amyloid deposition using the animal model of amyloid-A amyloidosis. Amyloid was induced by injection of amyloid enhancing factor (AEF) and silver nitrate (SN). Animals were sacrificed at 5 days and amyloid detected immunohistochemically using an antibody to serum amyloid A protein and quantitated by image analysis, as described in Methods.

Animal	AEF/SN	Control[a] untreated	AEF/SN + iAβ[b]
1	29.4	0.05	4.35
2	31.65	0.1	3.68
3	32.97	0.21	5.32
4	30.77	0.04	3.67
Average ± SE[c]	31.2 ± 0.75	0.10 ± 0.04	4.26 ± 0.39

[a] Represents the group of animals not treated with AEF/SN

[b] AEF (100 μg) was preincubated with 5 mg of IBAP1 for 24h and then injected together into the mice along with SN.

[c] Standard error

- 31 -

**Effect of iAβ on the promotion of Aβ fibrillogenesis
induced by apoliprotein E.**   It is thought that sAβ in human
body fluids is complexed to apolipoproteins, especially
apolipoprotein (apo) J and E (Maggio et al., *Proc. Natl. Acad.*

5   *Sci. USA* 89:5462-5466, 1992).   These proteins as well as
others (proteoglycans, amyloid P component, α1-
antichymotrypsin, etc) are found in senile plaques and
congophilic vessels (Tamaoka et al., *biochem. Biophys. Res.
Commun.* 205:834-842, 1994).   Several of these amyloid-

10 associated proteins bind to Aβ in solution and modulate the
rate of amyloid formation *in vitro* (Moore. G.J. *Trends
Pharmacol. Sci.* 15:124-129, 1994; Wisniewski et al., *Am. J.
Pathol.* 145:1030-1035, 1994; Ma et al., *Nature* 372:92-94,
1994; Snow et al., *Neuron.* 12:219-234, 1994).

15   The results shown in Fig. 18 show that iAβ blocked
the promotion of Aβ fibrillogenesis induced by apo E.
Preliminary experiments also indicate that heparan-sulfate
proteoglucan-induced Aβ fibrillogenesis is blocked as well by
iAβ.

20   **Dissolution of Alzheimer's amyloid plaque by iAβ.**
Amyloid was isolated from mature senile plaque extracted from
a brain of a patient who died of Alzheimer's disease.   Grey
matter was separated from meninges and white matter, cleaned,
chopped and homogenized in buffer containing 0.25M sucrose.

25 The homogenate was subjected to a series of centrifugation,
treatment with DNase I and collagenase and to a discontinuous
sucrose density gradient.   After this procedure, pure amyloid
cores containing >90% Aβ and also several of the amyloid-
associated proteins was obtained.   10 μg of amyloid proteins

30 was incubated for 5 days without and with 200 μg of iAβ.   The
amount of amyloid was quantitated by using the fluorometric
assay based in the binding of thioflavine T to amyloid, as
described (Soto, C., et al., *J. Biol. Chem.* 270: 3063-3067,
1995).   The material obtained from two different extractions

35 was tested (Samples 1 and 2) and the average and standard
error of three different experiments was shown.

          Effect of iAβ on Aβ-induced cell toxicity.   Neuronal
differentiated human neuroblastoma cells (IMR-32) were

obtained from American Type Culture Collection and were grown using the standard protocols. Fresh Aβ1-42 was added to the medium to reach a final concentration of 30 μM. The inhibitor (final concentration 600 μM) was added together or
5   preincubated with Aβ1-42 for 24h. After 48h cell toxicity was evaluated by using the lactate dehydrogenase (LDH) release assay (Simmons, et al., Mol. Pharmacol. 45: 373-379, 1994), using a kit obtained from Sigma. The results shown correspond to the average between two different experiments.
10   Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue
15   experimentation.

       While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or
20   adaptations of the inventions following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set
25   forth as follows in the scope of the appended claims.

       All references cited herein, including journal articles or abstracts, published or corresponding U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by
30   reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

       Reference to known method steps, conventional
35   methods steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

- 33 -

     The foregoing description of the specific
embodiments will so fully reveal the general nature of the
invention that others can, by applying knowledge within the
skill of the art (including the contents of the references
5 cited herein), readily modify and/or adapt for various
applications such specific embodiments, without undue
experimentation, without departing from the general concept of
the present invention. Therefore, such adaptations and
modifications are intended to be within the meaning and range
10 of equivalents of the disclosed embodiments, based on the
teaching and guidance presented herein. It is to be
understood that the phraseology or terminology herein is for
the purpose of description and not of limitation, such that
the terminology or phraseology of the present specification is
15 to be interpreted by the skilled artisan in light of the
teachings and guidance presented herein, in combination with
the knowledge of one of ordinary skill in the art.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

    (i) APPLICANT:
        (A) NAME: New York University
        (B) STREET: 70 Washigton Square South
        (C) CITY: New York
        (D) STATE: New York
        (E) COUNTRY: United States of America
        (F) POSTAL CODE (ZIP): 10012
        (G) TELEPHONE: (212) 263-8178
        (H) TELEFAX: (212) 263-8189

    (ii) TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
        THEREOF FOR TREATMENT OF DISORDERS OR DISEASES ASSOCIATED
        WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE DEPOSITS

    (iii) NUMBER OF SEQUENCES: 26

    (iv) CORRESPONDENCE ADDRESS:
        (A) ADDRESSEE: BROWDY AND NEIMARK
        (B) STREET: 419 Seventh Street, N.W., Suite 400
        (C) CITY: Washington
        (D) STATE: D.C.
        (E) COUNTRY: USA
        (F) ZIP: 20004

    (v) COMPUTER READABLE FORM:
        (A) MEDIUM TYPE: Floppy disk
        (B) COMPUTER: IBM PC compatible
        (C) OPERATING SYSTEM: PC-DOS/MS-DOS
        (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

    (vi) CURRENT APPLICATION DATA:
        (A) APPLICATION NUMBER: PCT
        (B) FILING DATE:

    (vii) PRIOR APPLICATION DATA:
        (A) APPLICATION NUMBER: US 08/478,326
        (B) FILING DATE: 06-JUN-1995

    (vii) PRIOR APPLICATION DATA:
        (A) APPLICATION NUMBER: US 08/630,645
        (B) FILING DATE: 10-APR-1996

    (viii) ATTORNEY/AGENT INFORMATION:
        (A) NAME: BROWDY, Roger L.
        (B) REGISTRATION NUMBER: 25,618
        (C) REFERENCE/DOCKET NUMBER: SOTO-JARA=1 PCT

    (ix) TELECOMMUNICATION INFORMATION:
        (A) TELEPHONE: 202-628-5197
        (B) TELEFAX: 202-737-3528

(2) INFORMATION FOR SEQ ID NO:1:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 8 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

. Lys Leu Val Phe Phe Ala Glu Asp
  1. _   5

(2) INFORMATION FOR SEQ ID NO:2:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 8 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

   (ii) MOLECULE TYPE: peptide

   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

    Arg Ser Phe Phe Ser Phe Leu Gly
    1   5

(2) INFORMATION FOR SEQ ID NO:3:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 8 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

   (ii) MOLECULE TYPE: peptide

   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

    Asp Cys Phe Ile Leu Asp Leu Gly
    1   5

(2) INFORMATION FOR SEQ ID NO:4:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 8 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

   (ii) MOLECULE TYPE: peptide

   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

    Arg Val Thr Ile Thr Cys Gln Ala
    1   5

(2) INFORMATION FOR SEQ ID NO:5:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 8 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

   (ii) MOLECULE TYPE: peptide

   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

    Ser Phe Tyr Leu Leu Tyr Tyr Thr
    1   5

(2) INFORMATION FOR SEQ ID NO:6:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 8 amino acids
            (B) TYPE: amino acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

    Asp Leu Ala Thr Val Tyr Val Asp
    1   5

(2) INFORMATION FOR SEQ ID NO:7:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 15 amino acids
            (B) TYPE: amino acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

    Ser Arg Gly Asp Leu Pro Phe Phe Pro Val Pro Ile Gly Asp Ser
    1   5   10   15

(2) INFORMATION FOR SEQ ID NO:8:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 11 amino acids
            (B) TYPE: amino acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

    Arg Asp Leu Pro Phe Phe Pro Val Pro Ile Asp
    1   5   10

(2) INFORMATION FOR SEQ ID NO:9:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 9 amino acids
            (B) TYPE: amino acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

    Arg Asp Phe Ile Pro Leu Pro Leu Asp
    1   5

(2) INFORMATION FOR SEQ ID NO:10:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 10 amino acids
            (B) TYPE: amino acid

                    (C) STRANDEDNESS: single
                    (D) TOPOLOGY: linear

        (ii) MOLECULE TYPE: peptide

        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

        Arg Asp Tyr Leu Pro Tyr Tyr Pro Leu Asp
        1   5   10

(2) INFORMATION FOR SEQ ID NO:11:

        (i) SEQUENCE CHARACTERISTICS:
                    (A) LENGTH: 18 amino acids
                    (B) TYPE: amino acid
                    (C) STRANDEDNESS: single
                    (D) TOPOLOGY: linear

        (ii) MOLECULE TYPE: peptide

        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

        Gly Lys Met Ser Ser Tyr Ala Phe Phe Val Gln Thr Cys Arg Glu Glu
        1   5   10   15

        His Lys

(2) INFORMATION FOR SEQ ID NO:12:

        (i) SEQUENCE CHARACTERISTICS:
                    (A) LENGTH: 15 amino acids
                    (B) TYPE: amino acid
                    (C) STRANDEDNESS: single
                    (D) TOPOLOGY: linear

        (ii) MOLECULE TYPE: peptide

        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

        Phe Asn Asn Gly Asp Cys Phe Ile Leu Asp Leu Gly Asn Asn Ile
        1   5   10   15

(2) INFORMATION FOR SEQ ID NO:13:

        (i) SEQUENCE CHARACTERISTICS:
                    (A) LENGTH: 15 amino acids
                    (B) TYPE: amino acid
                    (C) STRANDEDNESS: single
                    (D) TOPOLOGY: linear
        (ii) MOLECULE TYPE: peptide

        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

        Arg Ser Phe Phe Ser Phe Leu Gly Glu Ala Phe Asp Gly Ala Arg
        1   5   10   15

(2) INFORMATION FOR SEQ ID NO:14:

        (i) SEQUENCE CHARACTERISTICS:
                    (A) LENGTH: 11 amino acids
                    (B) TYPE: amino acid
                    (C) STRANDEDNESS: single
                    (D) TOPOLOGY: linear

        (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly
1   5   10

(2) INFORMATION FOR SEQ ID NO:15:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 9 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

    Arg Asp Leu Pro Phe Phe Pro Val Asp
    1   5

(2) INFORMATION FOR SEQ ID NO:16:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 7 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

    Leu Pro Phe Phe Pro Val Asp
    1   5

(2) INFORMATION FOR SEQ ID NO:17:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 6 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

    Leu Pro Phe Phe Val Asp
    1   5

(2) INFORMATION FOR SEQ ID NO:18:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 5 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

    Leu Pro Phe Phe Asp
    1   5

(2) INFORMATION FOR SEQ ID NO:19:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 4 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Leu Pro Phe Phe
1

(2) INFORMATION FOR SEQ ID NO:20:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 11 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Arg Asp Leu Pro Ile Val Pro Leu Pro Ile Asp
1   5   10

(2) INFORMATION FOR SEQ ID NO:21:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 7 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Leu Pro Ile Val Pro Leu Asp
1   5

(2) INFORMATION FOR SEQ ID NO:22:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 5 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Leu Pro Ile Val Asp
1   5

(2) INFORMATION FOR SEQ ID NO:23:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 12 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single

         (D) TOPOLOGY: linear

     (ii) MOLECULE TYPE: peptide

     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

     Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu
     1   5   10

(2) INFORMATION FOR SEQ ID NO:24:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 12 amino acids
            (B) TYPE: amino acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

       (ii) MOLECULE TYPE: peptide

       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

       Arg Asp Ala Pro Ala Ala Pro Val Val Pro Leu Asp
       1   5   10

(2) INFORMATION FOR SEQ ID NO:25:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 7 amino acids
            (B) TYPE: amino acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

       (ii) MOLECULE TYPE: peptide

       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

       Ala Ala Pro Val Val Pro Asp
       1   5

(2) INFORMATION FOR SEQ ID NO:26:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 12 amino acids
            (B) TYPE: amino acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

       (ii) MOLECULE TYPE: peptide

       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

       Val His Val Ser Glu Glu Gly Thr Glu Pro Glu Ala
       1   5   10

- 41 -

WHAT IS CLAIMED IS:

1. A method of preventing or treating a disorder or disease associated with the formation of amyloid or amyloid-like deposits involving the abnormal folding of a protein or peptide, comprising administering an effective amount of an inhibitory peptide to a subject in need thereof to prevent the abnormal folding of said protein or peptide into amyloid or amyloid-like deposits or dissolve existing amyloid or amyloid-like deposits, said inhibitory peptide comprising a sequence of three to about fifteen amino acid residues and having a hydrophobic cluster of at least three amino acids, wherein at least one of said at least three amino acids is a β-sheet blocking amino acid residue selected from Pro, Gly, Asn and His, and said inhibitory peptide is capable of associating with a structural determinant on said protein or peptide to structurally block and inhibit the abnormal folding thereof into amyloid or amyloid-like deposits.

2. The method in accordance with claim 1, wherein said protein or peptide is amyloid β-peptide.

3. The method in accordance with claim 1, wherein said protein or peptide is prion PrP protein.

4. The method in accordance with claim 1, wherein said subject is human.

5. The method in accordance with claim 4, wherein the disease is Alzheimer's.

6. The method in accordance with claim 4, wherein the disorder or disease is a prion-related encephalopathy.

7. The method in accordance with claim 1, wherein said subject is an animal.

8. The method in accordance with claim 1, wherein the structural determinant is a hydrophobic region having a high probability of forming a β-sheet conformation.

9. The method in accordance with claim 1, wherein said inhibitory peptide comprises a sequence between three and seven amino acid residues in length.

10. The method in accordance with claim 1, wherein at least some amino acid residues of said sequence are D-amino acid residues.

11. The method in accordance with claim 1, wherein at least some amino acid residues of said sequence are amino acid derivatives.

12. A method of detecting disorders or diseases associated with the formation of amyloid or amyloid-like deposits involving the abnormal folding of a protein or peptide, comprising the steps of:

labeling an inhibitory peptide comprising a sequence of three to about fifteen amino acid residues and having a hydrophobic cluster of at least three amino acids, wherein at least one of said three amino acids is a β-sheet blocking amino acid residue selected from Pro, Gly, Asn and His, said inhibitory peptide being capable of associating with a structural determinant on a protein or peptide present in amyloid or amyloid-like deposits;

administering said labeled inhibitory peptide to a subject to bind to structural determinants present in amyloid or amyloid-like deposits; and

detecting the presence of amyloid or amyloid-like deposits.

13. The method in accordance with claim 12, wherein the disease is Alzheimer's.

14. The method in accordance with claim 12, wherein the disorder or disease is a prion-related encephalopathy.

15. A peptide having an amino acid sequence consisting of a sequence selected from the group consisting of SEQ ID NO: 7, 8, 9, 10, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, and Pro-Phe-Phe.

16. The peptide in accordance with claim 15, wherein the peptide has the amino acid sequence of SEQ ID NO:8.

17. The method in accordance with claim 15, wherein at least some amino acid residues of said sequence are D-amino acid residues.

18. The method in accordance with claim 15, wherein at least some amino acid residues of said sequence are amino acid derivatives.

19. A pharmaceutical composition for treating

- 43 -

disorders or diseases associated with abnormal protein folding
into amyloid or amyloid-like deposits, comprising the peptide
of claim 15 and a pharmaceutically acceptable carrier.

20.   The pharmaceutical composition of claim 19,
wherein the peptide comprises the amino acid sequence of SEQ
ID NO:8.

FIG. 1A

PROTEIN	AMINO ACID SEQUENCE
ALZHEIMER'S β - AMYLOID	16 K L V F F <u>A E</u> D 23
AMYLOID A	1 R S F F S F L G 8
GELSOLIN AMYLOID	187 <u>D</u> C F I L D L G 194
AMYLOID L	18 R V T I T C Q A 25
β2 - MICROGLOBULIN AMYLOID	61 S F Y L L Y Y T 68
APOLIPOPROTEIN A1 AMYLOID	13 D L A T V Y V D 20

FIG. 1B

ALZHEIMER'S β - AMYLOID

AMYLOID A

GELSOLIN AMYLOID

AMYLOID L

β2 - MICROGLOBULIN AMYLOID

APOLIPOPROTEIN A1 AMYLOID

F I G. 2A

ANTI-AMYLOID 1   S R G D L P F F P V P I G D S
ANTI-AMYLOID 2   R D L P F F P V P I D
ANTI-AMYLOID 3   R D F I P L P L D
ANTI-AMYLOID 4   R D Y L P Y Y P L D

F I G. 2B

FIG.3

7-12 Å

N
C

N
C

N
C

N
C

4.7Å

FIBRIL DIRECTION

F I G . 4A

F I G . 4B

FIG.5A

FIG.5B

FIG.5C

F I G. 6A

F I G. 7A

PROTEIN	AMINO ACID SEQUENCE
AMPHOTERIN (HMG - 1)	10 G K M S S Y A F F V Q T C R E E H K 27

F I G. 7B

FIG. 6B

FIG. 7C

FIG. 8

- ▦ PEPTIDE ALONE
- ▨ PEPTIDE : INHIBITOR 1:5
- ▢ PEPTIDE : INHIBITOR 1:20

FIG. 9

iAβ   R D L P F F P V P I D

Aβ15-25 Q K L V F F A E D V G

F I G. 10

F I G. 11

F I G. 12

F I G. 13

F I G. 14A

F I G. 14B

FIG. 15A

FIG. 15B

FIG. 15C

FIG. 15D

FIG. 15E

FIG. 15F

F I G. 16

F I G. 17

FIG.18

FIG. 19

FIG. 20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/10220

A.	CLASSIFICATION OF SUBJECT MATTER
IPC(6)	:A01N 43/40, 43/42; A61K 31/44, 31/445, 49/00; G01N 31/00, 33/48
US CL	: 424/9.1, 9.341, 9.351; 514/2, 773; 530/300, 326, 327, 328, 329, 330, 331

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/9.1, 9.341, 9.351; 514/2, 773; 530/300, 326, 327, 328, 329, 330, 331

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Nature Medicine, Volume 1, Number 2, issued February 1995, Kisilevsky et al, "Arresting amyloidosis *in vivo* using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease", pages 143-148, see entire document.	1-11
A	Proc. Natl. Acad. Sci. USA, Volume 92, issued March 1995, Merlini et al, "Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis", pages 2959-2963, see entire document.	1-11
A --- Y	WO, A, 93/04194 (REGENTS OF THE UNIVERSITY OF MINNESOTA) 04 March 1993, see entire document.	1-11 --------- 12-20

[X]	Further documents are listed in the continuation of Box C.	[ ]	See patent family annex..

Date of the actual completion of the international search	Date of mailing of the international search report
28 AUGUST 1996	**17 SEP 1996**

Name and mailing address of the ISA/US	Authorized officer
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	PATRICIA A. DUFFY
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Y	Biochemical and Biophysical Research Communications, Volume 179, Number 3, issued 30 September 1991, Wisniewski et al, "Peptides Homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation", pages 1247-1254, see entire document.	15-20
Y	Biochemistry, Volume 32, Number 18, issued 11 May 1993, Jarrett et al, "The Carboxy Terminus of the β Amyloid Protein Is Critical for the Seeding of Amyloid Formation: Implications for the Pathogenesis of Alzheimer's Disease", pages 4693-4697, see entire document.	15-20
Y	The Journal of Neuroscience, Volume 13, Number 4, issued April 1993, Pike et al, "Neurodegeneration Induced by β-Amyloid Peptides *in vitro*: The Role of Peptide Assembly State", pages 1676-1686, see entire document.	15-20

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, BIOSYS, EMBASE, MEDLINE, JICST, JAPIO, DERWENT, CAB ABSTRACTS, EUROPEAN PATENTS; serarch terms: Alzheimer's Disease, Creutzfeldt-Jakob Disease, Gerstmann-Straussler-Scheinker Disease, scrapie spongiform encephalophathy, SEQ ID NOs:1-26, imaging agents, diagnosis or diagnostics or detection or screening, therapy or therapautics or treatment, plaques, inhibition, ameloriate, beta-amyoid, A4 peptide, amyloid peptide, deposition, aggregation, pharmaceutics or pharmaceutical.

THIS PAGE BLANK (USPTO)